📰 Robert Barrow News
Page 6 - Robert Barrow News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Robert Barrow. Real-time updates on events, politics, business and more.
January 11, 2024
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024.
January 1, 2024
Baird R W upgraded shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) to a strong-buy rating in a research report released on Wednesday morning, Zacks.com reports. Several other equities research analysts have also commented on MNMD. SVB Leerink started coverage on shares of Mind Medicine (MindMed) in a research note on Monday, April 15th. […]
December 27, 2023
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) CEO Robert Barrow sold 13,237 shares of the company’s stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $3.63, for a total transaction of $48,050.31. Following the transaction, the chief executive officer now owns 596,721 shares of the […]
December 18, 2023
A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.
December 14, 2023
Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the […]
December 14, 2023
Mind Medicine Inc. said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically...
November 3, 2023
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:
November 1, 2023
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Mind […]
October 3, 2023
– Preclinical data in ASD model demonstrate the differences between MM-402 , S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity – ...